Business
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence. Barzolvolimab is a humanized monoclonal a
About this update from Celldex Therapeutics, Inc.
[{"type":"image","alt":"Celldex Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Celldex Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":124,"url":"https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TpOULqxD5vaZLQ0RK_Jt6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/aef6fa6af72579028a194fa6d2556979","width":300,"height":124}},"lazy":false},{"type":"text","content":"- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab -","length":178,"tagName":"p"},{"type":"text","content":"HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of ColdU and SD—the mast cell. The data were shared today in a late breaking poster presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, PA. The data were presented by Jonathan A. Bernstein, MD, trial investigator and Professor of Clinical Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine.","length":833,"tagName":"p"},{"type":"text","content":"“Patients and physicians need treatment options that provide durable, symptom-free complete response and the potential for flexibility that reflects real world treatment paradigms,” said Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex. “We previously presented data in chronic spontaneous urticaria showing that up to 41% of patients continued to experience a complete response seven months after receiving their final dose on study. The data presented today from our inducible urticaria study demonstrate that when disease symptoms do recur, patients can be retreated and, importantly, achieve the same high levels of complete response they experienced on initial treatment. ...